# Efficacy of LCQ908 on Cardiovascular Risk

> **NCT01474434** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- Coronary Artery Disease
- Hypertriglyceridemia

## Interventions

- **DRUG:** pradigastat (LCQ908)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01474434
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** The study was terminated based on interim analysis. See detailed description.
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474434, "Efficacy of LCQ908 on Cardiovascular Risk". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01474434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*